Thalidomide in lepra reaction (ENL) in lepromatous leprosy patients.
Six male bacteriologically highly positive patients of lepromatous leprosy with ENL reaction not adequately controlled by conventional antireaction drugs were put on thalidomide 400 mg per day in four divided doses. Reaction was controlled between 13th to 18th day of therapy. There was no change in the bacteriological status. Liver functions, renal functions and hemogram were normal before therapy and remained unaltered at the end of treatment. Apart from fatigue, drowsiness and occassional constipation, thalidomide had no adverse effect. Control of ENL reaction by thalidomide in these patients is probably due to its immunosuppressive effect, more likely by its stablising action on lysosomes.
D004893:Erythema Nodosum / Q000188:drug therapy* / Q000378:metabolism; D006403:Hematologic Tests; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D012867:Skin / Q000382:microbiology; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D013792:Thalidomide